( December 15, 2025, 1:52 PM EST) -- NEW ORLEANS — Companies representing the interests of drug compounders “offer no sound reason to second-guess FDA’s reasonable determination” that the shortage of tirzepatide, an FDA-approved drug for diabetes and weight loss, had ended when it removed the drug from the agency’s drug shortage list, the Food and Drug Administration tells the Fifth Circuit U.S. Court of Appeals in a Dec. 12 brief, urging the appellate court to uphold a grant of summary judgment....